Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

著者: Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans, M. Roumiguié, Laurence E. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara L. Frenkl, Ronald de Wit - The Lancet 2021 被引用: 533